EP2516392 - SUBSTITUTED BENZAMIDE DERIVATIVES [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 16.06.2017 Database last updated on 03.09.2024 | |
Former | Examination is in progress Status updated on 04.11.2016 | Most recent event Tooltip | 16.06.2017 | Application deemed to be withdrawn | published on 19.07.2017 [2017/29] | Applicant(s) | For all designated states F. Hoffmann-La Roche AG Grenzacherstrasse 124 4070 Basel / CH | [N/P] |
Former [2012/44] | For all designated states F.Hoffmann-La Roche AG Grenzacherstrasse 124 4070 Basel / CH | Inventor(s) | 01 /
GROEBKE ZBINDEN, Katrin Laubibergstrasse 61 CH-4410 Liestal / CH | 02 /
NORCROSS, Roger Rheinfelderstrasse 2 CH-4305 Olsberg / CH | 03 /
PFLIEGER, Philippe 1 rue du Vignoble F-68130 Schwoben / FR | [2012/44] | Representative(s) | Poppe, Regina F.Hoffmann-La Roche AG Patent Department Grenzacherstrasse 124 4070 Basel / CH | [N/P] |
Former [2012/44] | Poppe, Regina F.Hoffmann-La Roche AG Patent Department Grenzacherstrasse 124 4070 Basel / CH | Application number, filing date | 10793256.8 | 17.12.2010 | WO2010EP70045 | Priority number, date | EP20090180504 | 22.12.2009 Original published format: EP 09180504 | [2012/44] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2011076678 | Date: | 30.06.2011 | Language: | EN | [2011/26] | Type: | A1 Application with search report | No.: | EP2516392 | Date: | 31.10.2012 | Language: | EN | The application published by WIPO in one of the EPO official languages on 30.06.2011 takes the place of the publication of the European patent application. | [2012/44] | Search report(s) | International search report - published on: | EP | 30.06.2011 | Classification | IPC: | C07D207/09, C07D207/10, C07D207/12, C07D211/26, C07D241/04, C07D265/30, C07D401/04, C07D401/12, C07D413/12, C07D413/14, C07D417/12, C07D417/14, A61K31/4025, A61K31/4523, A61K31/5355 | [2012/44] | CPC: |
C07D207/09 (EP,CN,US);
C07D207/06 (KR);
C07D413/14 (EP,CN,US);
A61K31/4025 (KR);
A61K9/2018 (EP,US);
A61P25/00 (EP);
A61P25/06 (EP);
A61P25/08 (EP);
A61P25/16 (EP);
A61P25/18 (EP);
A61P25/20 (EP);
A61P25/22 (EP);
A61P25/24 (EP);
A61P25/28 (EP);
A61P25/30 (EP);
A61P25/36 (EP);
A61P3/00 (EP);
A61P3/04 (EP);
A61P3/06 (EP);
A61P3/10 (EP);
A61P9/00 (EP);
A61P9/12 (EP);
C07D207/10 (EP,CN,US);
C07D207/12 (EP,CN,US);
C07D211/26 (EP,CN,US);
C07D241/04 (EP,CN,US);
C07D263/32 (EP,US);
C07D265/30 (EP,CN,US);
C07D267/08 (EP,CN,US);
C07D267/10 (EP,US);
C07D295/135 (EP,CN,US);
C07D401/04 (EP,CN,US);
C07D401/12 (EP,CN,KR,US);
C07D401/14 (EP,US);
C07D403/12 (EP,US);
C07D413/12 (EP,CN,US);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2012/44] | Title | German: | SUBSTITUIERTE BENZAMIDDERIVATE | [2012/44] | English: | SUBSTITUTED BENZAMIDE DERIVATIVES | [2012/44] | French: | DÉRIVÉS DE BENZAMIDE SUBSTITUÉS | [2012/44] | Entry into regional phase | 23.07.2012 | National basic fee paid | 23.07.2012 | Designation fee(s) paid | 23.07.2012 | Examination fee paid | Examination procedure | 19.08.2011 | Request for preliminary examination filed International Preliminary Examining Authority: EP | 23.07.2012 | Examination requested [2012/44] | 22.04.2014 | Despatch of a communication from the examining division (Time limit: M04) | 18.07.2014 | Reply to a communication from the examining division | 31.03.2015 | Despatch of a communication from the examining division (Time limit: M04) | 20.05.2015 | Reply to a communication from the examining division | 22.10.2015 | Despatch of a communication from the examining division (Time limit: M04) | 07.01.2016 | Reply to a communication from the examining division | 02.08.2016 | Despatch of a communication from the examining division (Time limit: M06) | 14.02.2017 | Application deemed to be withdrawn, date of legal effect [2017/29] | 13.03.2017 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2017/29] | Divisional application(s) | EP17151744.4 / EP3187490 | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 22.04.2014 | Fees paid | Renewal fee | 07.12.2012 | Renewal fee patent year 03 | 06.12.2013 | Renewal fee patent year 04 | 05.12.2014 | Renewal fee patent year 05 | 07.12.2015 | Renewal fee patent year 06 | 08.12.2016 | Renewal fee patent year 07 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [X]DE2123246 ((BADI ) BADISCHE ANILIN & SODA FAB AG) [X] 1,10,15,21 * page 8; examples 20-23, 25 *; | [X]US4636504 (ROSSY PHILLIP A [US], et al) [X] 1,12,15,16,18,21 * 6-{p-[3-(4-Phenyl-1-piperidino)-propionylamino]-phenyl}-5-methyl-4,5-dihydropyridazinone;; claim 7 *; | [X]US6184242 (BLEY KEITH ROGER [US], et al) [X] 1,4,14,15,21 * 2,2,2-trifluoro-N-[4-(piperidin-4-ylmethyl)-phenyl]acetamide; column 58, line 15 - line 16 *; | [X]US6444686 (KO SOO S [US], et al) [X] 1,2,15,16,18,21 * N-(2,5-Difluorophenyl)-N'-[[3-[[4-(phenylmethyl)-1-piperidinyl]methyl]phenyl]methyl]-urea; column 129; example 220 *; | [X]WO2004039764 (BOEHRINGER INGELHEIM PHARMA [DE], et al) [X] 1,2,8,15-21 * abstract * * page 128 - page 129; example 31 * * page 161; example 137 * * page 185; example 169 *; | [X]US2004157849 (LEE CHIH-HUNG [US], et al) [X] 1,10,15,16,18,21 * N-[4-(1-azepanyl)benzyl]-2-(5-isoquinolinyl)propanamide;; claim 55 *; | [X]WO2006077425 (ASTEX THERAPEUTICS LTD [GB], et al) [X] 1,4,15,16,18,21 * page 202 - page 203; example 230 * * page 4 - page 5 *; | [X]WO2007017728 (ORCHID RES LAB LTD [IN], et al) [X] 1,6,15,16,18,21 * page 31; compounds 50, 51 *; | [X]WO2007064818 (TEVA PHARMA [IL], et al) [X] 1,6,15,21 * 4-(4-morpholinyl)-N-benzyloxycarbonylaniline; page 12 *; | [A]US2009036420 (GALLEY GUIDO [DE], et al) [A] 1-21 * abstract * * claim 1 ** page 2, paragraph [0006] - paragraph [0026] *; | [X] - PERNER R J ET AL, "In vitro Structure-Activity Relationship and in vivo Characterization of 1-(Aryl)-3-(4-(amino)benzyl)urea transient Receptor Potential Vanilloid 1 Antagonists", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, US, vol. 50, no. 15, doi:DOI:10.1021/JM070276I, ISSN 0022-2623, (20070101), pages 3651 - 3660, (20070621), XP002591492 [X] 1,2,14-16,18,21 * page 3654; table 1; compounds 30-37, 39, 41 * * Scheme 1; page 3652 * DOI: http://dx.doi.org/10.1021/JM070276I | Examination | US4735959 | US2006111392 | US2007099919 | WO2008054702 | EP2009005 | EP2351744 | EP2401275 | - KISSLING-GUERIN, G. ET AL, "Anthranilic derivatives", CA, CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US, Database accession no. 1975:170296, URL: STN | - KISSLING-GUERIN, G. ET AL, "Anthranilic derivatives", BULLETIN DES TRAVAUX DE LA SOCIETE DE PHARMACIE DE LYON ISSN: 0037-9107, (1973), vol. 17, no. 4, pages 143 - 148 | - MANETTI F ET AL, "Building a pharmacophore model for a novel class of antitubercular compounds", IL FARMACO, ELSEVIER FRANCE - EDITIONS SCIENTIFIQUES ET MEDICALES, IT, (20000612), vol. 55, no. 6-7, ISSN 0014-827X, pages 484 - 491, XP008154241 DOI: http://dx.doi.org/10.1016/S0014-827X(00)00072-0 | - Mahima Verma ET AL, "Indolyl Compounds as Antiinflammatory Agents", Archiv der Pharmazie, Weinheim, (19820101), vol. 315, no. 4, doi:10.1002/ardp.19823150414, ISSN 0365-6233, pages 358 - 363, XP055221728 DOI: http://dx.doi.org/10.1002/ardp.19823150414 | by applicant | EP0717037 | WO9712874 | WO02076950 | WO2008098857 | - DEUTCH, A.Y.; ROTH, R.H., Neurotransmitters. In Fundamental Neuroscience, ACADEMIC PRESS, (1999), pages 193 - 234 | - WONG, M.L.; LICINIO, J., "Research and treatment approaches to depression", NAT. REV. NEUROSCI., (2001), vol. 2, doi:doi:10.1038/35072566, pages 343 - 351, XP009161506 DOI: http://dx.doi.org/10.1038/35072566 | - CARLSSON, A. ET AL., "Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence", ANNU. REV. PHARMACOL. TOXICOL, (2001), vol. 41, pages 237 - 260 | - TUITE, P.; RISS, J., "Recent developments in the pharmacological treatment of Parkinson's disease", EXPERT OPIN. INVESTIG. DRUGS, (2003), vol. 12, doi:doi:10.1517/eoid.12.8.1335.21771, pages 1335 - 1352, XP009023949 DOI: http://dx.doi.org/10.1517/eoid.12.8.1335.21771 | - CASTELLANOS, F.X.; TANNOCK, R., "Neuroscience of attention-deficit/hyperactivity disorder: the search for endophenotypes", NAT. REV. NEUROSCI., (2002), vol. 3, pages 617 - 628 | - LINDEMANN, L.; HOENER, M., "A renaissance in trace amines inspired by a novel GPCR family", TRENDS IN PHARMACOL. SCI, (2005), vol. 26, doi:doi:10.1016/j.tips.2005.03.007, pages 274 - 281, XP002498588 DOI: http://dx.doi.org/10.1016/j.tips.2005.03.007 | - BRANCHEK, T.A.; BLACKBURN, T.P., "Trace amine receptors as targets for novel therapeutics: legend, myth and fact.", CURR. OPIN. PHARMACOL., (2003), vol. 3, doi:doi:10.1016/S1471-4892(02)00028-0, pages 90 - 97, XP002284088 DOI: http://dx.doi.org/10.1016/S1471-4892(02)00028-0 | - PREMONT, R.T. ET AL., "Following the trace of elusive amines", PROC. NATL. ACAD. SCI. U. S. A., (2001), vol. 98, doi:doi:10.1073/pnas.181356198, pages 9474 - 9475, XP002284087 DOI: http://dx.doi.org/10.1073/pnas.181356198 | - MOUSSEAU, D.D.; BUTTERWORTH, R.F., "A high-affinity [3H] tryptamine binding site in human brain", PROG. BRAIN RES., (1995), vol. 106, pages 285 - 291 | - MCCORMACK, J.K. ET AL., "Autoradiographic localization of tryptamine binding sites in the rat and dog central nervous system", J. NEUROSCI., (1986), vol. 6, pages 94 - 101 | - DYCK, L.E., "Release of some endogenous trace amines from rat striatal slices in the presence and absence of a monoamine oxidase inhibitor", LIFE SCI., (1989), vol. 44, doi:doi:10.1016/0024-3205(89)90309-3, pages 1149 - 1156, XP025556497 DOI: http://dx.doi.org/10.1016/0024-3205(89)90309-3 | - PARKER, E.M.; CUBEDDU, L.X., "Comparative effects of amphetamine, phenylethylamine and related drugs on dopamine efflux, dopamine uptake and mazindol binding", J. PHARMACOL. EXP. THER, (1988), vol. 245, pages 199 - 210 | - LINDEMANN, L. ET AL., "Trace amine associated receptors form structurally and functionally distinct subfamilies of novel G protein-coupled receptors", GENOMICS, (2005), vol. 85, doi:doi:10.1016/j.ygeno.2004.11.010, pages 372 - 385, XP004779696 DOI: http://dx.doi.org/10.1016/j.ygeno.2004.11.010 | - GUO ET AL., ORG. LETT., (2008), vol. 10, pages 4513 - 4516 | - ORG. LETT., (2002), vol. 4, pages 973 - 976 | - ORG. LETT., (2007), vol. 9, pages 4749 - 4751 | - IYER ET AL., TETRAHEDRON. LETT., (2007), vol. 48, pages 4413 - 4418 |